These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 9265918

  • 21. Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release.
    Matsui-Sakata A, Ohtani H, Sawada Y.
    Drug Metab Pharmacokinet; 2005 Jun; 20(3):187-99. PubMed ID: 15988121
    [Abstract] [Full Text] [Related]

  • 22. Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome.
    Shirzadi AA, Ghaemi SN.
    Harv Rev Psychiatry; 2006 Jun; 14(3):152-64. PubMed ID: 16787887
    [Abstract] [Full Text] [Related]

  • 23. [Drug-induced akathisia].
    van Harten PN.
    Ned Tijdschr Geneeskd; 2002 Jan 19; 146(3):110-4. PubMed ID: 11826669
    [Abstract] [Full Text] [Related]

  • 24. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics.
    Miller CH, Mohr F, Umbricht D, Woerner M, Fleischhacker WW, Lieberman JA.
    J Clin Psychiatry; 1998 Feb 19; 59(2):69-75. PubMed ID: 9501888
    [Abstract] [Full Text] [Related]

  • 25. EPS profiles: the atypical antipsychotics are not all the same.
    Weiden PJ.
    J Psychiatr Pract; 2007 Jan 19; 13(1):13-24. PubMed ID: 17242588
    [Abstract] [Full Text] [Related]

  • 26. Medical complications of new antipsychotic drugs.
    Umbricht D, Kane JM.
    Schizophr Bull; 1996 Jan 19; 22(3):475-83. PubMed ID: 8873298
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Ondansetron for tardive dyskinesia.
    Zullino DF, Eap CB, Voirol P.
    Am J Psychiatry; 2001 Apr 19; 158(4):657-8. PubMed ID: 11282718
    [No Abstract] [Full Text] [Related]

  • 33. Atypical antipsychotics: mechanism of action.
    Seeman P.
    Can J Psychiatry; 2002 Feb 19; 47(1):27-38. PubMed ID: 11873706
    [Abstract] [Full Text] [Related]

  • 34. Atypical antipsychotics, tardive dyskinesia, and D(2) receptors.
    Duggal HS, Mendhekar DN.
    Am J Psychiatry; 2006 Aug 19; 163(8):1449-50. PubMed ID: 16877664
    [No Abstract] [Full Text] [Related]

  • 35. Safety of olanzapine.
    Beasley CM, Tollefson GD, Tran PV.
    J Clin Psychiatry; 1997 Aug 19; 58 Suppl 10():13-7. PubMed ID: 9265911
    [Abstract] [Full Text] [Related]

  • 36. Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses.
    McConville BJ, Sorter MT.
    J Clin Psychiatry; 2004 Aug 19; 65 Suppl 6():20-9. PubMed ID: 15104523
    [Abstract] [Full Text] [Related]

  • 37. A review and Bayesian meta-analysis of clinical efficacy and adverse effects of 4 atypical neuroleptic drugs compared with haloperidol and placebo.
    Klemp M, Tvete IF, Skomedal T, Gaasemyr J, Natvig B, Aursnes I.
    J Clin Psychopharmacol; 2011 Dec 19; 31(6):698-704. PubMed ID: 22020356
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.